Brain tumors may damage surrounding tissue in a more insidious way than previously understood. New research from the University of Notre Dame shows that chronic…
In oncology, the biggest constraints are not always science. They are often the logistics, the cost of specialized infrastructure, and…
An already approved cancer drug called Carfilzomib may help restore the effectiveness of CAR-T cell therapy in advanced multiple myeloma cases. Technical…
LIXTE recently announced advances in its approach to cancer therapy through its proprietary compound LB-100 Alongside clinical development news, LIXTE is…
Mass General Brigham researchers have developed a new AI model that can estimate brain age, assess a patient’s risk of developing dementia, and help predict survival…
Investors are responding positively to Meta’s decision to keep increasing artificial intelligence spending, even as fears grow that the AI boom could…
LIXTE Biotechnology recently acquired Liora Technologies, and the acquisition includes Liora’s proprietary LiGHT system This system provides several advantages over…
LIXTE’s lead compound, LB-100, targets PP2A, a central regulator of cancer cell survival and treatment resistance Clinical programs are designed…
Although cancer immunotherapy has transformed treatment for many patients, the promise of effective immunotherapy falls short for many patients. Scientists now believe they…
Power availability and control are emerging as binding constraints on AI data center growth, with efficient energy control now seen…